Hologic Inc.
Hologic Reports Strong Q1 2024 Financial Results, Exceeds Guidance
Summary
Hologic, Inc. announced its financial results for the first quarter of fiscal 2024 on February 1, 2024, revealing that it exceeded its guidance for both revenue and earnings. The company reported revenues of $1,013.1 million, a 5.7% decrease from the prior year, and GAAP diluted EPS of $1.03, significantly higher than the $0.75 reported in the same period last year. Hologic also provided updated financial guidance for the full year, expecting organic revenue growth and improved earnings. The company's strong cash flow and strategic initiatives, including a $500 million share repurchase agreement, underscore its commitment to enhancing shareholder value.
Profitelligence Alerts
Get alerts for HOLX
Be first to know when Hologic Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Hologic Inc.
Hologic Inc. is a leading global medical technology company focused on improving women's health and well-being. Its primary function is to develop, manufacture, and supply diagnostic products, medical imaging systems, and surgical products, which play crucial roles in the prevention and treatment of diseases. Hologic's key sectors include breast health, diagnostics, gynecological surgical, and skeletal health solutions. It is renowned for innovative technologies such as 3D mammography or tomosynthesis, which are significant advancements in breast cancer detection. With a commitment to enhancing healthcare quality and efficiency, Hologic operates across a diverse range of healthcare settings, from hospitals and clinics to laboratories and research facilities. Headquartered in Marlborough, Massachusetts, Hologic has established itself as a pivotal player in women's health diagnostics, contributing to its substantial market presence and influence in the global healthcare sector.
Official SEC Documents
Advertisement